Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FOCL
FocalTherics
$5.43
-0.9%
$0.00
$1.21
$5.64
$205.40M-0.0437,095 shs46,561 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$62.89
+1.4%
$61.90
$23.47
$68.99
$198.08M0.0178,266 shs234,749 shs
SkyAI, Inc. Common Stock stock logo
SKYA
SkyAI, Inc. Common Stock
$1.16
-1.7%
$1.43
$0.91
$18.23
$49.94M2.1340,148 shs79,392 shs
Biosig Technologies, Inc. stock logo
STEX
Biosig Technologies
$0.92
-0.3%
$1.02
$0.70
$7.44
$167.26M1.942.03 million shs553,729 shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FOCL
FocalTherics
-0.91%+4.83%+16.52%+542,999,900.00%+542,999,900.00%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
+1.37%+2.54%+1.47%+22.16%+28.37%
SkyAI, Inc. Common Stock stock logo
SKYA
SkyAI, Inc. Common Stock
-1.69%-5.69%+4.50%-30.54%-80.17%
Biosig Technologies, Inc. stock logo
STEX
Biosig Technologies
-0.26%-5.47%-0.41%-13.43%+91,759,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FOCL
FocalTherics
$5.43
-0.9%
$0.00
$1.21
$5.64
$205.40M-0.0437,095 shs46,561 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$62.89
+1.4%
$61.90
$23.47
$68.99
$198.08M0.0178,266 shs234,749 shs
SkyAI, Inc. Common Stock stock logo
SKYA
SkyAI, Inc. Common Stock
$1.16
-1.7%
$1.43
$0.91
$18.23
$49.94M2.1340,148 shs79,392 shs
Biosig Technologies, Inc. stock logo
STEX
Biosig Technologies
$0.92
-0.3%
$1.02
$0.70
$7.44
$167.26M1.942.03 million shs553,729 shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FOCL
FocalTherics
-0.91%+4.83%+16.52%+542,999,900.00%+542,999,900.00%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
+1.37%+2.54%+1.47%+22.16%+28.37%
SkyAI, Inc. Common Stock stock logo
SKYA
SkyAI, Inc. Common Stock
-1.69%-5.69%+4.50%-30.54%-80.17%
Biosig Technologies, Inc. stock logo
STEX
Biosig Technologies
-0.26%-5.47%-0.41%-13.43%+91,759,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
FOCL
FocalTherics
2.00
Hold$6.0010.50% Upside
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
2.67
Moderate Buy$70.0011.31% Upside
SkyAI, Inc. Common Stock stock logo
SKYA
SkyAI, Inc. Common Stock
1.00
SellN/AN/A
Biosig Technologies, Inc. stock logo
STEX
Biosig Technologies
2.00
Hold$8.00771.84% Upside

Current Analyst Ratings Breakdown

Latest SKYA, STEX, PDEX, and FOCL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
UpgradeHold (C+)Buy (B-)
6/2/2026
FOCL
FocalTherics
Reiterated RatingBuy$10.00
5/21/2026
Biosig Technologies, Inc. stock logo
STEX
Biosig Technologies
Lower Price TargetBuy$9.00 ➝ $8.00
5/19/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
UpgradeHold
5/12/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Boost Price TargetBuy$56.00 ➝ $70.00
5/1/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Reiterated RatingHold (C+)
5/1/2026
Biosig Technologies, Inc. stock logo
STEX
Biosig Technologies
UpgradeSell (E+)Sell (D-)
4/21/2026
SkyAI, Inc. Common Stock stock logo
SKYA
SkyAI, Inc. Common Stock
Reiterated RatingSell (E+)
(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
FOCL
FocalTherics
$70.53M2.89N/AN/A$0.52 per share10.44
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$66.59M3.01$3.18 per share19.78$11.23 per share5.60
SkyAI, Inc. Common Stock stock logo
SKYA
SkyAI, Inc. Common Stock
$200K245.46N/AN/A$9.12 per share0.13
Biosig Technologies, Inc. stock logo
STEX
Biosig Technologies
$40K4,170.49N/AN/A$0.83 per share1.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
FOCL
FocalTherics
-$29.25M-$0.81N/AN/AN/A-41.47%-137.61%-40.62%8/27/2026 (Estimated)
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$8.98M$3.6217.3722.62N/A16.08%22.78%14.30%9/3/2026 (Estimated)
SkyAI, Inc. Common Stock stock logo
SKYA
SkyAI, Inc. Common Stock
-$282.50M-$1.63N/AN/AN/AN/A-157.91%-154.40%9/2/2026 (Estimated)
Biosig Technologies, Inc. stock logo
STEX
Biosig Technologies
-$462.77M-$9.71N/AN/AN/AN/A-717.92%-336.75%N/A

Latest SKYA, STEX, PDEX, and FOCL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
SkyAI, Inc. Common Stock stock logo
SKYA
SkyAI, Inc. Common Stock
N/A-$1.19N/A-$1.19N/A$0.19 million
5/14/2026Q1 2026
Biosig Technologies, Inc. stock logo
STEX
Biosig Technologies
N/A-$0.27N/A-$0.27N/AN/A
5/7/2026Q1 2026
FOCL
FocalTherics
-$0.22-$0.24-$0.02-$0.24$19.46 million$20.48 million
4/30/2026Q3 2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$0.62$1.20+$0.58$1.20$17.90 million$19.95 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
FOCL
FocalTherics
N/AN/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/A
SkyAI, Inc. Common Stock stock logo
SKYA
SkyAI, Inc. Common Stock
N/AN/AN/AN/AN/A
Biosig Technologies, Inc. stock logo
STEX
Biosig Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
FOCL
FocalTherics
1.79
1.34
0.99
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.32
3.67
2.14
SkyAI, Inc. Common Stock stock logo
SKYA
SkyAI, Inc. Common Stock
N/A
8.28
8.08
Biosig Technologies, Inc. stock logo
STEX
Biosig Technologies
N/A
13.90
13.90

Institutional Ownership

CompanyInstitutional Ownership
FOCL
FocalTherics
62.74%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
15.28%
SkyAI, Inc. Common Stock stock logo
SKYA
SkyAI, Inc. Common Stock
17.17%
Biosig Technologies, Inc. stock logo
STEX
Biosig Technologies
7.16%

Insider Ownership

CompanyInsider Ownership
FOCL
FocalTherics
10.10%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
45.90%
SkyAI, Inc. Common Stock stock logo
SKYA
SkyAI, Inc. Common Stock
20.00%
Biosig Technologies, Inc. stock logo
STEX
Biosig Technologies
52.73%
CompanyEmployeesShares OutstandingFree FloatOptionable
FOCL
FocalTherics
23037.48 million33.70 millionN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
1403.19 million1.73 millionNot Optionable
SkyAI, Inc. Common Stock stock logo
SKYA
SkyAI, Inc. Common Stock
5542.32 million33.86 millionNot Optionable
Biosig Technologies, Inc. stock logo
STEX
Biosig Technologies
50181.80 million85.94 millionN/A

Recent News About These Companies

Streamex Corp. Provides May 2026 Shareholder Update

New MarketBeat Followers Over Time

Media Sentiment Over Time

FocalTherics NASDAQ:FOCL

$5.43 -0.05 (-0.91%)
As of 07/10/2026 04:00 PM Eastern

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.

Pro-Dex stock logo

Pro-Dex NASDAQ:PDEX

$62.89 +0.85 (+1.37%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$62.85 -0.04 (-0.06%)
As of 07/10/2026 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

SkyAI, Inc. Common Stock stock logo

SkyAI, Inc. Common Stock NASDAQ:SKYA

$1.16 -0.02 (-1.69%)
As of 07/10/2026 04:00 PM Eastern

SkyAI Inc is developing financial technology platforms focused on users in emerging markets. Its operations include the use of stablecoin-based payment infrastructure and artificial intelligence (AI) technologies to provide financial access, educational tools, and data analysis services for users in Asia, Latin America, and Africa. The company's platform will utilize the Solana blockchain network to support digital asset and on-chain data applications.

Biosig Technologies stock logo

Biosig Technologies NASDAQ:STEX

$0.92 0.00 (-0.26%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$0.90 -0.02 (-2.14%)
As of 07/10/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.